Matching articles for "Rozerem"
Issue 1667 · January 9, 2023
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

View the Expanded Table: Some Oral Drugs for Chronic Insomnia

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e6-10 doi:10.58347/tml.2023.1667b
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Issue 1667 · January 9, 2023
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training,…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):1-6 doi:10.58347/tml.2023.1667a
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Issue 1654 · July 11, 2022
Daridorexant (Quviviq) for Insomnia

The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):107-10
The FDA has approved daridorexant ( Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Issue 1601 · June 29, 2020
Lemborexant (Dayvigo) for Insomnia

The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be…

Med Lett Drugs Ther. 2020 Jun 29; 62(1601):97-100
The FDA has approved lemborexant ( Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant ( Belsomra ) was the first.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1562 · December 17, 2018
Expanded Table: Some Oral Hypnotics for Insomnia (online only)

View the Expanded Table: Some Oral Hypnotics for Insomnia

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):e209-13
View the Expanded Table: Some Oral Hypnotics for Insomnia
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 1466 · April 13, 2015
Advice for Travelers

Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their…

Med Lett Drugs Ther. 2015 Apr 13; 57(1466):52-8
Patients planning to travel to other countries often ask for information about prevention of diarrhea, malaria, and other travel-related conditions. Vaccines recommended for travelers based on their destination, length of stay, and planned activities were reviewed in a previous issue.
Issue 1463 · March 2, 2015
Suvorexant (Belsomra) for Insomnia

The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.

Med Lett Drugs Ther. 2015 Mar 2; 57(1463):29-31
The FDA has approved suvorexant ( Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Issue 1441 · April 28, 2014
Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder

The FDA has approved the melatonin receptor agonist tasimelteon ( Hetlioz – Vanda) for treatment of non-24-hour sleep-wake disorder (non-24), which is common in totally blind persons. Tasimelteon is the…

Med Lett Drugs Ther. 2014 Apr 28; 56(1441):34-5
The FDA has approved the melatonin receptor agonist tasimelteon ( Hetlioz – Vanda) for treatment of non-24-hour sleep-wake disorder (non-24), which is common in totally blind persons. Tasimelteon is the first drug approved for this indication and the second melatonin receptor agonist approved for use in the US; ramelteon (Rozerem) was approved earlier for treatment of insomnia. Melatonin itself has not been approved by the FDA for any indication; it is available in the US as a dietary supplement and is promoted as a sleep aid.
Issue 119 · July 1, 2012
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.

Treat Guidel Med Lett. 2012 Jul; 10(119):57-60
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications and "natural" remedies. Behavioral changes are often needed as well.
Issue 1348 · October 4, 2010
Low-Dose Doxepin (Silenor) for Insomnia

The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this…

Med Lett Drugs Ther. 2010 Oct 4; 52(1348):79-80
The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.
Issue 79 · March 1, 2009
Drugs for Insomnia

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar; 7(79):23-6
The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 42 · February 1, 2006
Drugs for Insomnia

Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than…

Treat Guidel Med Lett. 2006 Feb; 4(42):5-10
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than treatment with drugs. Hypnotic drugs are generally FDA-approved only for short-term use, but in practice they often are taken much longer.
Issue 1223 · December 5, 2005
Ambien CR for Insomnia

Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):97-8
Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received FDA approval to market an extended-release formulation of the drug, Ambien CR . The pharmacological rationale for doing so is that short-acting hypnotics like zolpidem are more effective at inducing sleep than they are at maintaining it.
Issue 1221 · November 7, 2005
Ramelteon (Rozerem) for Insomnia

Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which…

Med Lett Drugs Ther. 2005 Nov 7; 47(1221):89-91
Ramelteon ( Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.